The Antineoplastic Agent Paclitaxel (Taxol®) Increases Contractile Activity in Human Saphenous Veins and Human Mammary Arteries

GOMEZ ALVIS ALICIA; RINALDI GUSTAVO; REBOLLEDO ALEJANDRO; MILESI VERONICA; SANZ NORA; TOMMASI JUAN; GRASSI DE GENDE ANGELA

CANCER INVESTIGATION

TAYLOR & FRANCIS INC

Lugar: Londres; Año: 2000 vol. 18 p. 327 - 335

0735-7907

Effects of the antineoplastic agent paclitu.xe1 (Taxol@:w) pre ytudied on contmctionsof isolated human saphenous vein (HSV) and mammary urteiy (HMA). Peak.forcedeveloped by vascular segments with cumulative concentrations of physiologic agonistrwas enhanced by paelitaxel, producing a shqt to the left of dose-responsecurves. Paclituxel I pM decreased ED5 ,( in ,&foIr )no repinephrine from 1.01 -f0.24 to 0.20 ? 0.06 (n = 16, p < 0.05) in HSV and from 1.30 2 0.30 to 0.51 ?0.21 (n = 15, p < 0.05) in HMA and for 5-hydroxytriptumine from 0.64 5 0.19 to0.21 ? 0.07 (n = 20, p < 0.05) in HSV. Paclitaxel 1 pM also signijkantly increasedthe peak force of contractions elicited by endothelin-I 0.01 pA4 in HSV. In contrast,it did not affect contractions evoked by KC1 80 mM. These results show that paclitaxelproduces a hyperreactivity in human vessels challenged by physiologic agonists,which suggests that administration of paelitaxel to patients could augmentperipheral resistance and increase blood pressure